Enhancing Immunogenicity in Metastatic Melanoma: Adjuvant Therapies to Promote the Anti-Tumor Immune Response

Advanced melanoma is an aggressive form of skin cancer characterized by low survival rates. Less than 50% advanced patients respond to current therapies, and those that do respond, many present with tumor recurrence due resistance. The immunosuppressive tumor-immune microenvironment (TIME) remains a major obstacle in therapy. Adjuvant treatment modalities enhance anti-tumor immune cell function are associated improved patient response. One potential mechanism stimulate the response inducing immunogenic death (ICD) tumors. ICD leads release damage-associated molecular patterns within TIME, subsequently promoting antigen presentation immunity. This review summarizes relevant concepts mechanisms underlying introduces non-ablative low-intensity focused ultrasound (LOFU) as immune-priming therapy can be combined ICD-inducing focal ablative therapies promote anti-melanoma